Abatacept
Phase 2Recruiting 1 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Interstitial Lung Disease
Conditions
Interstitial Lung Disease, Common Variable Immunodeficiency
Trial Timeline
Jul 14, 2021 → Jul 1, 2026
NCT ID
NCT04925375About Abatacept
Abatacept is a phase 2 stage product being developed by Bristol Myers Squibb for Interstitial Lung Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04925375. Target conditions include Interstitial Lung Disease, Common Variable Immunodeficiency.
What happened to similar drugs?
1 of 5 similar drugs in Interstitial Lung Disease were approved
Approved (1) Terminated (2) Active (3)
✅Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05170672 | Pre-clinical | Completed |
| NCT05981976 | Phase 1 | Completed |
| NCT04925375 | Phase 2 | Recruiting |
| NCT04472494 | Phase 2 | Terminated |
| NCT04477642 | Phase 1/2 | Withdrawn |
| NCT03924401 | Phase 2 | Active |
| NCT03882008 | Approved | Completed |
| NCT03669861 | Phase 2 | Completed |
| NCT03714022 | Phase 1 | Completed |
| NCT03084419 | Phase 2 | UNKNOWN |
| NCT03215927 | Phase 2 | Completed |
| NCT02915159 | Phase 3 | Completed |
| NCT02805010 | Phase 1 | UNKNOWN |
| NCT02037737 | Pre-clinical | Completed |
| NCT02592798 | Phase 2 | Completed |
| NCT02598466 | Pre-clinical | Completed |
| NCT02281058 | Phase 1 | UNKNOWN |
| NCT02078882 | Approved | Completed |
| NCT01954979 | Phase 1 | Completed |
| NCT02169544 | Pre-clinical | Completed |
Competing Products
20 competing products in Interstitial Lung Disease